These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 19692354)

  • 21. Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.
    Yokota T; Nakamura A; Nagata T; Saito T; Kobayashi M; Aoki Y; Echigoya Y; Partridge T; Hoffman EP; Takeda S
    Nucleic Acid Ther; 2012 Oct; 22(5):306-15. PubMed ID: 22888777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.
    Cao L; Han G; Gu B; Yin H
    PLoS One; 2014; 9(11):e111079. PubMed ID: 25365558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.
    Yin H; Saleh AF; Betts C; Camelliti P; Seow Y; Ashraf S; Arzumanov A; Hammond S; Merritt T; Gait MJ; Wood MJ
    Mol Ther; 2011 Jul; 19(7):1295-303. PubMed ID: 21505427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy.
    Maruyama R; Echigoya Y; Caluseriu O; Aoki Y; Takeda S; Yokota T
    Methods Mol Biol; 2017; 1565():201-213. PubMed ID: 28364245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy.
    Lim KRQ; Woo S; Melo D; Huang Y; Dzierlega K; Shah MNA; Aslesh T; Roshmi RR; Echigoya Y; Maruyama R; Moulton HM; Yokota T
    Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35193974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy.
    Yokota T; Hoffman E; Takeda S
    Methods Mol Biol; 2011; 709():299-312. PubMed ID: 21194037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.
    Jearawiriyapaisarn N; Moulton HM; Sazani P; Kole R; Willis MS
    Cardiovasc Res; 2010 Feb; 85(3):444-53. PubMed ID: 19815563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
    Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted skipping of human dystrophin exons in transgenic mouse model systemically for antisense drug development.
    Wu B; Benrashid E; Lu P; Cloer C; Zillmer A; Shaban M; Lu QL
    PLoS One; 2011; 6(5):e19906. PubMed ID: 21611204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice.
    Mizobe Y; Miyatake S; Takizawa H; Hara Y; Yokota T; Nakamura A; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1828():275-292. PubMed ID: 30171548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro.
    Chen S; Le BT; Chakravarthy M; Kosbar TR; Veedu RN
    Sci Rep; 2019 Apr; 9(1):6078. PubMed ID: 30988454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials.
    Popplewell LJ; Adkin C; Arechavala-Gomeza V; Aartsma-Rus A; de Winter CL; Wilton SD; Morgan JE; Muntoni F; Graham IR; Dickson G
    Neuromuscul Disord; 2010 Feb; 20(2):102-10. PubMed ID: 20079639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice.
    Wu B; Xiao B; Cloer C; Shaban M; Sali A; Lu P; Li J; Nagaraju K; Xiao X; Lu QL
    Mol Ther; 2011 Mar; 19(3):576-83. PubMed ID: 21179007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice.
    Vila MC; Novak JS; Benny Klimek M; Li N; Morales M; Fritz AG; Edwards K; Boehler JF; Hogarth MW; Kinder TB; Zhang A; Mazala D; Fiorillo AA; Douglas B; Chen YW; van den Anker J; Lu QL; Hathout Y; Hoffman EP; Partridge TA; Nagaraju K
    J Pathol; 2019 Jul; 248(3):339-351. PubMed ID: 30883742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle.
    Novak JS; Hogarth MW; Boehler JF; Nearing M; Vila MC; Heredia R; Fiorillo AA; Zhang A; Hathout Y; Hoffman EP; Jaiswal JK; Nagaraju K; Cirak S; Partridge TA
    Nat Commun; 2017 Oct; 8(1):941. PubMed ID: 29038471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective exon skipping and dystrophin restoration by 2'-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice.
    Yang L; Niu H; Gao X; Wang Q; Han G; Cao L; Cai C; Weiler J; Yin H
    PLoS One; 2013; 8(4):e61584. PubMed ID: 23658612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment.
    Betts CA; McClorey G; Healicon R; Hammond SM; Manzano R; Muses S; Ball V; Godfrey C; Merritt TM; van Westering T; O'Donovan L; Wells KE; Gait MJ; Wells DJ; Tyler D; Wood MJ
    Hum Mol Genet; 2019 Feb; 28(3):396-406. PubMed ID: 30281092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.
    Relizani K; Goyenvalle A
    Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges.
    Arechavala-Gomeza V; Anthony K; Morgan J; Muntoni F
    Curr Gene Ther; 2012 Jun; 12(3):152-60. PubMed ID: 22533380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers.
    Williams JH; Sirsi SR; Latta DR; Lutz GJ
    Mol Ther; 2006 Jul; 14(1):88-96. PubMed ID: 16488666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.